➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Patent: 8,257,729

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,257,729
Title:Implants with membrane diffusion-controlled release of active ingredient
Abstract: An implant for implantation in a human or animal body having a structure comprising a) an implant base body; b) a primer layer which is partially or completely applied to the surface of the implant; c) an active ingredient layer consisting of one, two, three or more active ingredients applied entirely or partially to the surface of the primer layer; and d) a diffusion-controlling layer which is applied partially or entirely to the active ingredient layer, and optionally to the primer layer, wherein diffusion of the active ingredients of the active ingredient layer is controlled. Also disclosed is a manufacturing method for an implant.
Inventor(s): Schmitz; Klaus-Peter (Warnemuende, DE), Behrend; Detlef (Rostock, DE), Sternberg; Katrin (Rostock, DE), Grabow; Niels (Rostock, DE), Harder; Claus (Uttenreuth, DE), Klocke; Bjoern (Zurich, CH), Kroemer; Heyo K. (Neuenkirchen, DE), Weitschies; Werner (Neuenkirchen, DE)
Assignee: Biotronik VI Patent AG (Baar, CH) Universitaet Rostock (Rostock, DE) Universitaet Greifswald (Greifswald, DE)
Application Number:12/331,567
Patent Claims:see list of patent claims

Details for Patent 8,257,729

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial Biotronik VI Patent AG (Baar, CH) Universitaet Rostock (Rostock, DE) Universitaet Greifswald (Greifswald, DE) 2027-12-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.